Specialized blood tests such as antinuclear antibody (ANA) tests are sometimes useful in the diagnosis or categorization of both localized and systemic scleroderma, as well as overlapping or other autoimmune diseases. (Also see:What is Scleroderma?, Types of Scleroderma and Systemic Symptoms)
Functional autoantibodies in systemic sclerosis (SSc) pathogenesis. Functional autoantibodies could represent a significant piece in the puzzle of SSc pathogenesis and may open new gateways and opportunities for therapeutic intervention. PubMed, Curr Rheumatol Rep, 2015 May;17(5):505.
Autoantibodies and SLE-the threshold for disease. The current findings are summarized regarding the presence of SLE-associated antibodies in apparently healthy individuals, and provide opinions on what such discoveries might tell us about the roles of autoantibodies in the development of disease. PubMed, Nat Rev Rheumatol, 2013 Dec 3. (Also see Systemic Lupus Erythematosus Antibodies)
New Autoantibodies in early Rheumatoid Arthritis. These autoantibodies could be used as diagnosis markers in RA patients. PubMed, Arthritis Res Ther, 2013 Jul 25;15(4):R78. (Also see Rheumatoid Arthritis)
Autoantibody profile and clinical correlation in a group of patients with systemic sclerosis (SSc) in southern Brazil. This study emphasizes and confirms the important role of autoantibodies in assessing patients with SSc, allowing the correlation between the autoimmune profile of patients with SSc and specific manifestations of the disease. Müller CD. Rev Bras Reumatol, 2011 Aug;51(4):319-324.
ESR: Erythrocyte Sedimentation Rate. There are different methods of obtaining the SED rate--such as Westergren, Cutler, Wintrobe, and Smith--and what is considered normal will depend on the method used. This test can be used to monitor inflammatory or cancerous diseases. It is a screening test, which means it cannot be used to diagnose a specific disorder. Medline Plus.
ANCA and Anti-PR3
AT1R and ETAR
DNA, Topoisomerase I
ESR (Sed Rate)
PmScl and dsDNA
TNF and IL-13
IgG or IgM anti-Cu/Zn SOD antibody was detected in the serum of 89% of localized scleroderma patients, especially 100% of patients with generalized morphea, the severest form of localized scleroderma, but was positive only in the serum of less than 15% of patients with other autoimmune disorders, including systemic sclerosis, systemic lupus erythematosus, dermatomyositis, and autoimmune bullous disorders. Journal of Investigative Dermatology. (Also see Generalized Morphea)
Antinucleosome antibody is a major autoantibody in localized scleroderma. Although antinucleosome antibody was not specific to localized scleroderma, its high prevalence in localized scleroderma indicates that antinucleosome antibody is a major autoantibody in this disease. PubMed, Br J Dermatol. (Also see Localized Scleroderma)
Antibodies in Lupus. There are over 100 antibodies associated with lupus. ISN.
Anti-NKG2A autoantibodies in a patient with systemic lupus erythematosus (SLE). NKG2A autoantibodies are rare, but when they occur they may contribute to the pathogenesis by increasing the killing of cells and the release of autoantigens. PubMed, Rheumatology (Oxford), 2013 Jul 3.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, Volunteer, or Donate.
International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report or update any page content or links.
Toll Free US/Canada Scleroderma Hotline: 800-564-7099